Your session is about to expire
← Back to Search
Kinase Inhibitor
Loncastuximab + Acalabrutinib for Chronic Lymphocytic Leukemia
Phase 1
Recruiting
Led By Mayur Narkhede, M.D.
Research Sponsored by Mayur Narkhede
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
On therapy with acalabrutinib for a minimum of 3 months without evidence of progression as per IWCLL 2018 criteria.
Immunophenotype consistent with CLL defined as the predominant population of lymphocytes share both B cell antigens (CD19, CD20 (typically dim expression), or CD23) as well as CD5 in the absence of other pan-T-cell markers (CD3, CD2, etc).
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new combination of drugs (Loncastuximab Tesirine and Aclabrutinib) for treating chronic lymphocytic leukemia. The main goal is to find
Who is the study for?
This trial is for people with chronic lymphocytic leukemia (CLL) who have been on Acalabrutinib for at least 3 months without disease progression. Participants must have had prior CLL treatment, measurable residual disease, and adequate kidney and liver function. They should not be using G-CSF within 7 days of joining the study.
What is being tested?
The study aims to find the highest dose of Loncastuximab Tesirine that can be safely added to Acalabrutinib in treating CLL without causing severe side effects. It's an early-phase trial focusing on dosage levels.
What are the potential side effects?
Potential side effects may include reactions where the drug enters the body, changes in blood counts leading to increased infection risk or bleeding problems, liver issues, fatigue, and possible kidney-related complications.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I've been on acalabrutinib for 3+ months with no cancer progression.
Select...
My leukemia cells show specific markers that indicate CLL.
Select...
My blood or bone marrow test shows remaining cancer.
Select...
My kidneys work well enough (crcl > 30ml/min).
Select...
My blood counts meet the required levels and I haven't used G-CSF in the last week.
Select...
I have CLL that came back or didn't respond to treatment and have had at least one prior therapy before starting acalabrutinib.
Select...
I have been diagnosed with small lymphocytic lymphoma or CLL with high lymphocyte counts.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Primary Objective
Secondary study objectives
Secondary Objective 1
Secondary Objective 2
Secondary Objective 3
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
4Treatment groups
Experimental Treatment
Group I: Dose level 4:Experimental Treatment1 Intervention
90 µg /kg Loncastuximab Tesirine (for first 2 cycles followed by 75µg/kg for subsequent 10 cycles) + Acalabrutinib 100 mg BID for a total of 12 cycles.
Group II: Dose Level 3Experimental Treatment1 Intervention
75 µg/kg Loncastuximab Tesirine every 21 days + Acalabrutinib 100 mg BID for 12 cycles
Group III: Dose Level 2Experimental Treatment1 Intervention
60 µg/kg Loncastuximab Tesirine every 21 days + Acalabrutinib 100 mg BID for 12 cycles
Group IV: Dose Level 1:Experimental Treatment1 Intervention
45 µg/kg Loncastuximab Tesirine every 21 days + Acalabrutinib 100 mg BID for 12 cycles
Find a Location
Who is running the clinical trial?
Mayur NarkhedeLead Sponsor
ADC Therapeutics S.A.Industry Sponsor
30 Previous Clinical Trials
2,548 Total Patients Enrolled
Mayur Narkhede, M.D.Principal InvestigatorUniversity of Alabama at Birmingham